Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19
Public ClinicalTrials.gov record NCT04779879. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-Blind, Parallel Group Phase II Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a Second Generation VIR-7831 Material in Non-Hospitalized Participants With Mild to Moderate Coronavirus Disease 2019 (COVID-19)
Study identification
- NCT ID
- NCT04779879
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Vir Biotechnology, Inc.
- Industry
- Enrollment
- 354 participants
Conditions and interventions
Conditions
Interventions
- Sotrovimab (Gen1) Biological
- Sotrovimab (Gen2) Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years to 69 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 17, 2021
- Primary completion
- Aug 19, 2021
- Completion
- Apr 5, 2022
- Last update posted
- May 2, 2023
2021 – 2022
United States locations
- U.S. sites
- 18
- U.S. states
- 8
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigative Site | Anniston | Alabama | 36207 | — |
| Investigative Site | Bakersfield | California | 93301 | — |
| Investigative Site | Northridge | California | 91325 | — |
| Investigative Site | Ft. Pierce | Florida | 34982 | — |
| Investigative Site | Gainesville | Florida | 32607 | — |
| Investigative Site | Hialeah | Florida | 33016 | — |
| Investigative Site | Miami | Florida | 33125 | — |
| Investigative Site | Miami | Florida | 33135 | — |
| Investigative Site | Miami | Florida | 33155 | — |
| Investigative Site | Miami | Florida | 33176 | — |
| Investigative Site | Orlando | Florida | 32803 | — |
| Investigative Site | Pembroke Pines | Florida | 33024 | — |
| Investigative Site | Tampa | Florida | 33614 | — |
| Investigative Site | Columbus | Georgia | 31904 | — |
| Investigative Site | Winfield | Illinois | 60190 | — |
| Investigative Site | Rockville | Maryland | 20850 | — |
| Investigative Site | The Bronx | New York | 10456 | — |
| Investigative Site | Houston | Texas | 77090 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04779879, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 2, 2023 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04779879 live on ClinicalTrials.gov.